Steroidogenic Factor-1 Regulates Transcription of the Human Anti-müllerian Hormone Receptor

Pascal de Santa Barbara, Brigitte Moniot, Françis Poulat, Brigitte Boizet, Philippe Berta

Journal of Biological Chemistry · 1998 · 75 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Anti-müllerian hormone type II receptor (AMHRII) is a serine/threonine receptor and a member of type II receptors of the transforming growth factor β superfamily. AMHRII has been recently identified in humans, mice, rats, and rabbits. In the male embryo, the AMHRII gene has been shown to be expressed in Sertoli's cells, in Leydig's cells and in the mesenchymal cells surrounding the müllerian duct. To determine the functional region of the AMHRII promoter as well as the factors controlling AMHRII gene expression, we used a 1.1-kilobase DNA fragment from the 5′-flanking region of the human AMHRII gene to generate a series of deletion or mutation and analyzed the resulting transcriptional activities after transfection of the NT2/D1 teratocarcinoma cell line. Our results indicate that maximal expression of the AMHRII promoter in this particular cell line, a cell line positive for endogenous AMHRII expression, requires a conserved estrogen receptor half-site element (AGGTCA) identical to the binding element for steroidogenic factor-1 (SF-1). Studies of this SF-1 binding element using gel mobility shift, antibody supershift assays, and transient transfections of reporter constructs indicate that SF-1 can bind and transactivate the AMHRII promoter. Finally, SF-1 protein expression in human male embryos was shown to display a good coincidence with the previously reported AMHRII expression profile. We then propose that SF-1 may be a key transcriptional regulator of AMHRII gene expression during early human development. Anti-müllerian hormone type II receptor (AMHRII) is a serine/threonine receptor and a member of type II receptors of the transforming growth factor β superfamily. AMHRII has been recently identified in humans, mice, rats, and rabbits. In the male embryo, the AMHRII gene has been shown to be expressed in Sertoli's cells, in Leydig's cells and in the mesenchymal cells surrounding the müllerian duct. To determine the functional region of the AMHRII promoter as well as the factors controlling AMHRII gene expression, we used a 1.1-kilobase DNA fragment from the 5′-flanking region of the human AMHRII gene to generate a series of deletion or mutation and analyzed the resulting transcriptional activities after transfection of the NT2/D1 teratocarcinoma cell line. Our results indicate that maximal expression of the AMHRII promoter in this particular cell line, a cell line positive for endogenous AMHRII expression, requires a conserved estrogen receptor half-site element (AGGTCA) identical to the binding element for steroidogenic factor-1 (SF-1). Studies of this SF-1 binding element using gel mobility shift, antibody supershift assays, and transient transfections of reporter constructs indicate that SF-1 can bind and transactivate the AMHRII promoter. Finally, SF-1 protein expression in human male embryos was shown to display a good coincidence with the previously reported AMHRII expression profile. We then propose that SF-1 may be a key transcriptional regulator of AMHRII gene expression during early human development. anti-müllerian hormone anti-müllerian hormone type II receptor steroidogenic factor-1 electrophoresis mobility shift assay kilobase(s) polymerase chain reaction base pair(s) glutathione S-transferase. Anti-müllerian hormone (AMH),1 also known as müllerian inhibiting substance, is a glycoprotein dimer that belongs to the growing family of the transforming growth factors β (1Jost A. Recent Prog. Horm. Res. 1953; 8: 379-418Google Scholar). AMH, the earliest product secreted by Sertoli's cells, plays a critical role during early male fetal sex differentiation by inducing the regression of the müllerian ducts, the anlagen of the uterus, the Fallopian tubes, and the upper vagina. In the last 4 years, major progress has been realized in our understanding of AMH action by the isolation of its receptor (2Baarends W.M. van Helmond M.J.L. Post M. van der Schoot P.J.C.M. Hoogerbrugge J.W. de Winter J.P. Uilenbroek J.T.J. Karels B. Wilming L.G. Meijers J.H.C. Themmen A.P.N. Grootegoed J.A. Development. 1994; 120: 189-197Crossref PubMed Google Scholar, 3di Clemente N. Wilson C. Faure E. Boussin L. Carmillo P. Tizard R. Picard J.Y. Vigier B. Josso N. Cate R. Mol. Endocrinol. 1994; 8: 1006-1020Crossref PubMed Scopus (199) Google Scholar, 4Teixera J. He W.W. Shah P.C. Morikawa N. Lee M.M. Catlin E.A. Hudson P.L. Wing J. MacLaughlin D.T. Donahoe P.K. Endocrinology. 1996; 137: 160-165Crossref PubMed Scopus (122) Google Scholar). Members of the transforming growth factor β family signal through a heteromeric signaling complex composed of two related type I and II receptors, both transmembrane serine/threonine kinases (5Wrana J.L. Tran H. Attisano L. Arora K. Childs S.R. Massagué J. O'Connor M.B. Mol. Cell. Biol. 1994; 14: 944-950Crossref PubMed Scopus (132) Google Scholar). Type II receptors appear able to bind their ligands independently of type I components, but activation of the corresponding signal transduction pathway will require the presence of the two types of receptor (6Massagué J. Cell. 1996; 85: 947-950Abstract Full Text Full Text PDF PubMed Scopus (804) Google Scholar). As a transforming growth factor β family member, AMH does not escape this rule and the receptor cloned in humans, mice, rats, and rabbits is an AMH type II receptor (AMHRII). Formal proof to equate this receptor with the AMH receptor came from the production of AMHRII mouse mutants using targeted mutagenesis (7Mishina Y. Rey R. Finegold M.J. Matzuk M.M. Josso N. Cate R.L. Behringer R.R. Genes Dev. 1996; 10: 2577-2587Crossref PubMed Scopus (277) Google Scholar). The mutant mice harbor the same resulting phenotype observed in AMH mutant as internal pseudohermaphrodites with uterine and oviductal tissues, a condition known in humans as persistent müllerian duct syndrome (8Guerrier D. Tran D. van der Winden J.M. Hideux S. Van Outryve L. Legeai L. Bouchard L. van Vliet G. de Laet M.H. Picard J.Y. Khan A. Josso N. J. Clin. Endocrinol. Metab. 1989; 68: 46-52Crossref PubMed Scopus (103) Google Scholar, 9Imbeaud S. Carré-Eusèbe D. Rey R. Belville C. Josso N. Picard J.Y. Hum. Mol. Genet. 1994; 3: 125-131Crossref PubMed Scopus (92) Google Scholar). Simultaneously, analysis of developmental expression of AMHRII was reported by many groups in different models but always at the transcript level (2Baarends W.M. van Helmond M.J.L. Post M. van der Schoot P.J.C.M. Hoogerbrugge J.W. de Winter J.P. Uilenbroek J.T.J. Karels B. Wilming L.G. Meijers J.H.C. Themmen A.P.N. Grootegoed J.A. Development. 1994; 120: 189-197Crossref PubMed Google Scholar, 3di Clemente N. Wilson C. Faure E. Boussin L. Carmillo P. Tizard R. Picard J.Y. Vigier B. Josso N. Cate R. Mol. Endocrinol. 1994; 8: 1006-1020Crossref PubMed Scopus (199) Google Scholar, 4Teixera J. He W.W. Shah P.C. Morikawa N. Lee M.M. Catlin E.A. Hudson P.L. Wing J. MacLaughlin D.T. Donahoe P.K. Endocrinology. 1996; 137: 160-165Crossref PubMed Scopus (122) Google Scholar). All these data agree with an expression for AMHRII at the right time and right place in male embryos,i.e. in the window of sensitivity of the müllerian duct to AMH within the mesenchyme cells surrounding the male müllerian epithelium where AMH elicits its action (10Tsuji M. Shima H. Yonemura C.Y. Brody J. Donahoe P.K. Cunha G.R. Endocrinology. 1992; 124: 1481-1488Crossref Scopus (51) Google Scholar). In these studies, other cellular sites of AMHRII expression are also depicted in Sertoli's and granulosa cells of both fetal and adult gonads. More recently, expression of AMHRII on Leydig's cells was also reported (11Racine C. Rey R. Forest M.G. Louis F. Ferré A. Huhtaniemi I. Josso N. di Clemente N. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 594-599Crossref PubMed Scopus (201) Google Scholar). A striking coincidence between AMH and AMHRII receptor expressions has led to diverse speculations on a putative autocrine feedback control of AMH (3di Clemente N. Wilson C. Faure E. Boussin L. Carmillo P. Tizard R. Picard J.Y. Vigier B. Josso N. Cate R. Mol. Endocrinol. 1994; 8: 1006-1020Crossref PubMed Scopus (199) Google Scholar, 12Grootegoed J.A. Baarends W.M. Themmen A.P.N. Mol. Cell. Endocrinol. 1994; 100: 29-34Crossref PubMed Scopus (19) Google Scholar). These results also open the possibility that a similar combinatorial transcription factor complex is used to control both genes. Previous studies reported that AMH expression is under the control of a 180-bp DNA fragment including a single estrogen receptor half-site (AGGTCA) recognized by a protein designated steroidogenic factor 1 (SF-1) (13Shen W.H. Moore C.C.D. Ikeda Y. Parker K.L. Ingraham H.A. Cell. 1994; 77: 651-661Abstract Full Text PDF PubMed Scopus (466) Google Scholar). The functional importance of the AMH proximal promoter was supported by several observations including the coincident expression profile between SF-1 and AMH (13Shen W.H. Moore C.C.D. Ikeda Y. Parker K.L. Ingraham H.A. Cell. 1994; 77: 651-661Abstract Full Text PDF PubMed Scopus (466) Google Scholar, 14Giuli G. Shen W.H. Ingraham H.A. Development. 1997; 124: 1799-1807PubMed Google Scholar). Beyond this particular function during the sex determining process in Sertoli's cells, SF-1 was also shown to be important in the development of the hypothalamic-pituitary-gonadal axis or in the development of different endocrine tissues (15Ingraham H.A. Lala D.S. Ikeda Y. Luo X. Shen W.H. Nachtigal M.W. Abbud R. Nilson J.H. Parker K.L. Genes Dev. 1994; 8: 2302-2312Crossref PubMed Scopus (496) Google Scholar, 16Kastner P. Mark M. Chambon P. Cell. 1995; 83: 859-869Abstract Full Text PDF PubMed Scopus (912) Google Scholar). Because of the parallelism in the expression profile of both anti-müllerian hormone and AMHRII receptors, we now address the possibility that regulation of the two genes could use common factors. Thus, in the present study we first determined a minimal promoter activity within a 1.1-kb DNA fragment from the 5′-flanking of the human AMHRII gene. Then we identified the presence of a conserved SF-1 binding site in this sequence and demonstrated its functional requirement in the regulation of the AMHRII gene. Finally, using immunolocalization studies the developmental pattern of expression of the SF-1 protein was shown to be coincident with AMHRII expression described in previous reports. Human AMHRII DNA 5′ flanking sequences were generated by PCR using genomic DNA as a template and were next extended with a human PromoterFinderTM DNA Walking kit (CLONTECH). The sequences and positions of the two specific primers were as follows. The forward primer, 5′-CCACATAGCAAAATTTACCATTG-3′, is complementary to the human AMHRII genomic sequence deposited in GenBankTM under accession number U29700 and corresponds to nucleotides −544 to −522, whereas the reverse primer, 5′-CTTGCTGGAGGATGGCAGCAGC AG-3′, is complementary to that of nucleotides +81 to +56 (numbering from the transcription start site previously defined (21Imbeaud S. Faure E. Lamarre I. Mattéi M.G. di Clemente N. Tizard R. Carré-Eusèbe D. Belville C. Tragethon L. Tonkin C. Nelson J. McAuliffe M. Bidart J.M. Lababidi A. Josso N. Cate R.L. Picard J.Y. Nat. Genet. 1995; 11: 382-388Crossref PubMed Scopus (185) Google Scholar)). The amplification product was cloned into pUC18 (SureClone ligation kit, Amersham Pharmacia Biotech). DNA sequence was determined to verify identity with AMHRII sequence. The human PromoterFinderTM DNA Walking kit was used with the reverse GSP1 reverse primer 5′-GCCCTTCCCTGACCTTGGAAGAAGA-3′ corresponding to nucleotides −253 to −277 in the first reaction and with the GSP2 reverse primer GAAAACAGTAACAATGGTAAATTT corresponding to nucleotides −511 to −534 (Fig. 1). The 1.1-kb AMHRII 5′-flanking region was finally reconstructed into the pUC18 plasmid with the help of an endogenousBglII restriction site located at position −375 bp and was fully sequenced. The reporter gene construct was generated using the pGL family of luciferase reporter vectors (Stratagene). The −1058/+78-AMHR-pUC18 plasmid was used as a template to amplify AMHRII promoter DNA from positions −1058 to +78 by PCR. The forward and reverse primers contain, respectively, the recognition sites for KpnI and XhoI. After KpnI-XhoI digestion, one copy of the 1136-bp PCR product was inserted in theKpnI-XhoI sites of pGL3-promoter vector. This construct will be referred to as −1058/+78-pGL3p. The same strategy was used to produce −546/+78-pGL3p and −257/+78-pGL3p deletion mutants. −1054/−374 was created by BglII hydrolysis of the −1058/+78-pGL3p construct. Site-directed mutagenesis of the SF-1 binding site to produce −1058SF-1MUT-pGL3p was performed using the QuickChangeTM site-directed mutagenesis kit (Stratagene) with the help of the RAMH-MUT oligonucleotide (see below). Full-length SF-1 cDNA was cloned as a BamHI and EcoRI fragment into the pcDNA3 vector, which directs transcription from the cytomegalovirus promoter as described previously. 2de Santa Barbara, P., Bonneaud, N., Boizet, B., Desclozeaux, M., Moniot, B., Sudbeck, P., Scherer, G., Poulat, F., and Berta, P. (1998) Mol. Cell. Biol., in press. Nuclear extracts from NT2/D1, HeLa, and transfected HeLa cells were prepared from freshly haversted cultured cells according to the method of Dignam et al. (17Dignam J.D. Lebovitz R.M. Roeder R.G. Nucleic Acids Res. 1983; 11: 1475-1489Crossref PubMed Scopus (9058) Google Scholar). For SF-1 transfected HeLa cells, 60–80% confluence cells were transfected with 2 μg of SF-1 expression plasmid and 7 μl of LipofectAMINE (Life for 4 The extracts were then prepared after of The expression was used to produce the protein in the after by After 2 of at cells were by in 1 and with I Pharmacia and and for at 4 were by at for The was on and with I and with II were by gel electrophoresis analysis and then used for in assay studies after from the with II glutathione after of at 4 binding to AMHRII promoter DNA was by the mobility shift assay For these were by of in the presence of and DNA polymerase fragment for 1 at The was on a gel and in at were at for in μl μg of extracts or to 2 μg of Pharmacia and For or supershift an oligonucleotide or an antibody was for at the The were on a gel in at 4 by and then The DNA used in these were complementary DNA including the SF-1 binding site from the AMHRII promoter or the SF-1 binding site from the AMH promoter The sequences of the of the are as and The nucleotides are in The human NT2/D1 cell line a human cell was from the Type NT2/D1, HeLa, and cells were cultured in fetal (Life and 2 with of at in used for transfections were using the HeLa, or NT2/D1 cells at 60–80% confluence were with and then with of reporter of luciferase control promoter used as an internal control for transfection and SF-1 expression plasmid with μl of LipofectAMINE (Life in μl of After 4 of the was with μl of with and cells were after of were with the activities were expressed as luciferase activity and the of Human tissues were from of as of a by both the from and by the were according to the R. 1983; PubMed Scopus Google Scholar). The were from and demonstrated to be male by polymerase chain reaction as described N., J. Berta, P., N., N., M., and R. Hum. Scholar). were by an at with the previously described and fully or respectively, with a and a in After in were with or with and In were performed for in the same described for the were and in were and on a or on a The human AMH receptor type II gene has been previously cloned (2Baarends W.M. van Helmond M.J.L. Post M. van der Schoot P.J.C.M. Hoogerbrugge J.W. de Winter J.P. Uilenbroek J.T.J. Karels B. Wilming L.G. Meijers J.H.C. Themmen A.P.N. Grootegoed J.A. Development. 1994; 120: 189-197Crossref PubMed Google Scholar, 3di Clemente N. Wilson C. Faure E. Boussin L. Carmillo P. Tizard R. Picard J.Y. Vigier B. Josso N. Cate R. Mol. Endocrinol. 1994; 8: 1006-1020Crossref PubMed Scopus (199) Google Scholar, 4Teixera J. He W.W. Shah P.C. Morikawa N. Lee M.M. Catlin E.A. Hudson P.L. Wing J. MacLaughlin D.T. Donahoe P.K. Endocrinology. 1996; 137: 160-165Crossref PubMed Scopus (122) Google Scholar). As a first to its transcriptional we the recently 5′-flanking sequence (21Imbeaud S. Faure E. Lamarre I. Mattéi M.G. di Clemente N. Tizard R. Carré-Eusèbe D. Belville C. Tragethon L. Tonkin C. Nelson J. McAuliffe M. Bidart J.M. Lababidi A. Josso N. Cate R.L. Picard J.Y. Nat. Genet. 1995; 11: 382-388Crossref PubMed Scopus (185) Google by polymerase chain and this sequence was extended by a As shown in sequence analysis of the resulting not or A E. P. H. R. Nucleic Acids Res. 1996; PubMed Scopus Google for identified two sites and one site and two to the transcription site recently defined (21Imbeaud S. Faure E. Lamarre I. Mattéi M.G. di Clemente N. Tizard R. Carré-Eusèbe D. Belville C. Tragethon L. Tonkin C. Nelson J. McAuliffe M. Bidart J.M. Lababidi A. Josso N. Cate R.L. Picard J.Y. Nat. Genet. 1995; 11: 382-388Crossref PubMed Scopus (185) Google Scholar). this analysis and previous analysis (21Imbeaud S. Faure E. Lamarre I. Mattéi M.G. di Clemente N. Tizard R. Carré-Eusèbe D. Belville C. Tragethon L. Tonkin C. Nelson J. McAuliffe M. Bidart J.M. Lababidi A. Josso N. Cate R.L. Picard J.Y. Nat. Genet. 1995; 11: 382-388Crossref PubMed Scopus (185) Google a SF-1 element conserved in the mouse was at positions to identical DNA element located in the AMH minimal promoter has led recently to the of SF-1 in the regulation of AMH expression (13Shen W.H. Moore C.C.D. Ikeda Y. Parker K.L. Ingraham H.A. Cell. 1994; 77: 651-661Abstract Full Text PDF PubMed Scopus (466) Google Scholar). To its transcription this 1.1-kb DNA fragment was to the luciferase reporter gene and then transfected in NT2/D1, HeLa or cell As shown in 2 the 1.1-kb DNA sequence luciferase expression in NT2/D1 cells In this fragment not expression in HeLa or These results that a promoter activity is present in the of sequence but also the cell of this The NT2/D1 cell line has been shown to not the genes described as in the sex C. R. Hum. Mol. Genet. PubMed Scopus Google and F. F. C. X. B. N. P. J. Biol. 1995; Scopus Google and data not an endogenous expression of the AMHRII gene in the NT2/D1 cells was by reverse assay that this cell line is a to AMHRII transcriptional regulation not A series of reporter constructs was to putative transcription factor binding sites within the promoter. The results of this analysis are in 2 B. or site-directed mutagenesis of the SF-1 binding site in a in the AMHRII promoter activity to the 1.1-kb promoter. All the activities were using transient transfection in the NT2/D1 cell line. To the SF-1 in the study bind the corresponding we the binding of SF-1 to this sequence from the human AMHRII promoter. were using protein and a oligonucleotide corresponding to the AMHRII promoter SF-1 (Fig. A the complex was by an and by including results were were using extracts prepared from NT2/D1 cell line, a cell line endogenous The gel shift was by with a sequence from the AMHRII receptor or the AMH promoter and was by including the SF-1 antibody (Fig. Finally, as a were also performed using extracts prepared from HeLa cells or from HeLa cells after transfection with a SF-1 expression plasmid SF-1 under the control of the cytomegalovirus minimal and (Fig. and these results demonstrated that SF-1 transcription factor can bind in to the AMHRII gene promoter. We next the functional importance of this in For this reporter the 1.1-kb AMHRII promoter region to the luciferase were transfected into HeLa cells with As shown in the 5′-flanking region of the AMHRII gene has by to luciferase activity in HeLa cells, a cell line that endogenous SF-1 protein (13Shen W.H. Moore C.C.D. Ikeda Y. Parker K.L. Ingraham H.A. Cell. 1994; 77: 651-661Abstract Full Text PDF PubMed Scopus (466) Google of of SF-1 expression plasmid has led to a reporter This activation was after mutation of the SF-1 binding site to SF-1 protein binding (Fig. the level of activation with a of these results on the of SF-1 to the AMHRII promoter and the requirement of an SF-1 binding site to this also that SF-1 not require a or a to AMHRII This with the that SF-1 by was to the AMH promoter in HeLa cells (13Shen W.H. Moore C.C.D. Ikeda Y. Parker K.L. Ingraham H.A. Cell. 1994; 77: 651-661Abstract Full Text PDF PubMed Scopus (466) Google Scholar). data been recently on this requirement for SF-1 S. A. S. Mol. Endocrinol. 1998; PubMed Google Scholar). In the of our results not the of other factors that could but also AMHRII expression to specific the AMHRII expression profile the one described for AMH in A. R. Development. PubMed Google Scholar). that SF-1 AMHRII gene in came from analysis of the expression pattern of SF-1 by to a between SF-1 and AMHRII expression of AMHRII has been analyzed (2Baarends W.M. van Helmond M.J.L. Post M. van der Schoot P.J.C.M. Hoogerbrugge J.W. de Winter J.P. Uilenbroek J.T.J. Karels B. Wilming L.G. Meijers J.H.C. Themmen A.P.N. Grootegoed J.A. Development. 1994; 120: 189-197Crossref PubMed Google Scholar, 3di Clemente N. Wilson C. Faure E. Boussin L. Carmillo P. Tizard R. Picard J.Y. Vigier B. Josso N. Cate R. Mol. Endocrinol. 1994; 8: 1006-1020Crossref PubMed Scopus (199) Google Scholar, 4Teixera J. He W.W. Shah P.C. Morikawa N. Lee M.M. Catlin E.A. Hudson P.L. Wing J. MacLaughlin D.T. Donahoe P.K. Endocrinology. 1996; 137: 160-165Crossref PubMed Scopus (122) Google and J. Donahoe P.K. J. 1996; Google Scholar). In this expression in the with müllerian duct in fetal Sertoli's and granulosa This expression was recently extended to the Leydig's cell (11Racine C. Rey R. Forest M.G. Louis F. Ferré A. Huhtaniemi I. Josso N. di Clemente N. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 594-599Crossref PubMed Scopus (201) Google Scholar). sites of expression during the or adult are also J. Donahoe P.K. J. 1996; Google Scholar). The of a specific antibody with an to SF-1 expression during human at the level of the protein a human we a expression for SF-1 in Sertoli's cells also by their AMH expression (Fig. 1 and a expression was also in cells the tubes, in the Leydig's cells (Fig. 1 and this developmental SF-1 expression was also in the mesenchymal cells surrounding the müllerian a where the AMHRII is also known to be expressed (Fig. In an male human embryo, SF-1 signal the müllerian duct (Fig. This is in with previous AMHRII expression during müllerian duct regression in the (2Baarends W.M. van Helmond M.J.L. Post M. van der Schoot P.J.C.M. Hoogerbrugge J.W. de Winter J.P. Uilenbroek J.T.J. Karels B. Wilming L.G. Meijers J.H.C. Themmen A.P.N. Grootegoed J.A. Development. 1994; 120: 189-197Crossref PubMed Google or in the (3di Clemente N. Wilson C. Faure E. Boussin L. Carmillo P. Tizard R. Picard J.Y. Vigier B. Josso N. Cate R. Mol. Endocrinol. 1994; 8: 1006-1020Crossref PubMed Scopus (199) Google Scholar). In the present that AMHRII gene activation may require a DNA binding element for the a member of the receptor family located in the AMH type II receptor proximal promoter. The present data with previous AMHRII gene expression (2Baarends W.M. van Helmond M.J.L. Post M. van der Schoot P.J.C.M. Hoogerbrugge J.W. de Winter J.P. Uilenbroek J.T.J. Karels B. Wilming L.G. Meijers J.H.C. Themmen A.P.N. Grootegoed J.A. Development. 1994; 120: 189-197Crossref PubMed Google Scholar, 3di Clemente N. Wilson C. Faure E. Boussin L. Carmillo P. Tizard R. Picard J.Y. Vigier B. Josso N. Cate R. Mol. Endocrinol. 1994; 8: 1006-1020Crossref PubMed Scopus (199) Google Scholar, 4Teixera J. He W.W. Shah P.C. Morikawa N. Lee M.M. Catlin E.A. Hudson P.L. Wing J. MacLaughlin D.T. Donahoe P.K. Endocrinology. 1996; 137: 160-165Crossref PubMed Scopus (122) Google Scholar, J. Donahoe P.K. J. 1996; Google the first that SF-1 could an role in the transcriptional control of the AMHRII promoter. using the AMHRII promoter described may now be a to the role of the SF-1 binding site in this a strategy recently used for AMH G. Shen W.H. Ingraham H.A. Development. 1997; 124: 1799-1807PubMed Google Scholar). The of the conserved DNA binding sites present in their other in their of In this both and described recently to to AMH regulation C. J.M. M. Development. 1998; PubMed Google will to to AMHRII This possibility is now under We for of the and R. Rey for the

References

23